Legal Representation
Attorney
Stephanie H. Bald
USPTO Deadlines
Application History
46 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 26, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Dec 25, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jul 24, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jul 24, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jul 24, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jul 24, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jul 24, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Apr 26, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 25, 2023 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Apr 18, 2023 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Apr 24, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Apr 18, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 17, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 30, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 28, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Sep 28, 2022 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Sep 28, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 16, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 14, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Apr 14, 2022 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Apr 14, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 29, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 27, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Oct 27, 2021 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Oct 27, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 25, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 21, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 21, 2021 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| May 21, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 21, 2021 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| May 21, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| May 21, 2021 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Nov 24, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 29, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 29, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 9, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 24, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 21, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 20, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 20, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 27, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 27, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 27, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 26, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 30, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 26, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals for human use, namely, pharmaceuticals for prevention and treatment of inflammatory, autoimmune, genetic, neurological, metabolic, infectious, hematological, musculo-skeletal, degenerative, cardiovascular, respiratory, gastrointestinal, endocrinological, dermatological, genitourinary, ophthalmological, oncological, and nephrological diseases and conditions mediated via intracellular transport processes
Class 042
Pharmaceutical research and development services
Classification
International Classes
005
042